Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions

Industry

โดย GuruFocus·Read original

Summary · why it matters

Novo Nordisk shares rose about 2% on Wednesday after new prescription data showed its oral weight-loss drug Wegovy captured an estimated 89% share of U.S. prescriptions for the two once-daily oral obesity medicines. The report, based on IQVIA data for the week ended July 3, indicated the Wegovy pill generated about 153,050 U.S. prescriptions, compared with roughly 19,550 for Eli Lilly's Foundayo, giving Eli Lilly about 11% of the market. Novo Nordisk introduced the oral version of Wegovy earlier this year, while Eli Lilly launched Foundayo in April, and JPMorgan noted that Wegovy has maintained a sizable lead even after accounting for the earlier market entry. During Week 13 of its U.S. rollout, the Wegovy pill recorded about 105,000 prescriptions, more than five times Foundayo's tally at a comparable stage. The prescription trends have prompted analysts to revise forecasts, with Deutsche Bank lowering its 2026 sales estimate for Foundayo to $1.3 billion from about $3 billion, while FactSet consensus projections for the Wegovy pill have more than doubled to about $2.2 billion for 2026.